JPMorgan Chase & Co. cut its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 31.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 244,613 shares of the biotechnology company’s stock after selling 110,442 shares during the quarter. JPMorgan Chase & Co. owned 0.30% of BioCryst Pharmaceuticals worth $1,360,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 45 shares in the last quarter. Legal & General Group Plc boosted its position in shares of BioCryst Pharmaceuticals by 4.9% during the 2nd quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 860 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth about $126,000. Bank of America Corp DE lifted its holdings in shares of BioCryst Pharmaceuticals by 43.3% in the 1st quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 7,568 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 4.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 1,500 shares during the last quarter. 70.19% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have issued reports on the company. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. ValuEngine cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. Finally, BidaskClub cut BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, August 18th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $8.78.
In other news, Director Fred E. Cohen sold 54,250 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the sale, the director now owns 173,660 shares in the company, valued at approximately $941,237.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 5.80% of the company’s stock.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) opened at 4.16 on Friday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $3.75 and a 52 week high of $9.25. The stock’s market cap is $334.58 million. The firm’s 50 day moving average price is $5.18 and its 200-day moving average price is $5.45.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $3.10 million during the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The business’s revenue was down 35.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.22) EPS. Analysts expect that BioCryst Pharmaceuticals, Inc. will post ($0.75) EPS for the current year.
TRADEMARK VIOLATION WARNING: “JPMorgan Chase & Co. Trims Holdings in BioCryst Pharmaceuticals, Inc. (BCRX)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/jpmorgan-chase-co-reduces-holdings-in-biocryst-pharmaceuticals-inc-bcrx.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.